Since its inception in 2009, Xavier University's RCIVII Center for Cancer Research has been a driving force toward achieving the University's goal of becoming a national leader in cancer and health disparities research. We propose five alms in order to move closer to attaining this goal. (1) Strengthen internal and external collaborations and partnerships, particularly those that promote health disparities and translational research: building on existing collaborations with LSU, LSU Health Sciences Center, Tulane University and the Pennington Biomedical Research Center through active partnerships in the Louisiana Cancer Research Consortium and the Louisiana Biomedical Research Network, we will leverage research and mentoring resources in place and establish new ones via partnerships formed within Xavier and between Xavier and RTRN institutions. (2) Reorganize and enhance critical core facilities: we will down size one existing core, create a new core in drug discovery and delivery and add -a bioinformatics facility to our existing Cell and Molecular Biology Core. (3) Increase Xavier's pool of competitive and productive cancer and health disparities researchers who participate in the translational research pipeline: we will retain previously hired, now competitive, RCMI faculty, hire additional promising junior faculty in critical gap areas that will improve our capabilities in health disparities and translational research, and provide these faculty with the resources necessary to become/remain competitive. (4)Establish a new pilot project program for cancer/health disparities research: we will use a peer-reviewed mechanism to select projects that will increase Xavier NIH R01 and other R-series grants and support pilot translational research projects for preliminary data collection. (5) Provide targeted administrative services in support of RCMI investigators: we will assure that faculty needs are met with minimal burden, research programs and core services are integrated and encourage teamwork, and that faculty development programs promote professional growth and engagement in health disparities and translational research. Successfully completing these aims will be significant because it will increase the pool of researchers who can more quickly translate bench discoveries into public benefit, particularly in minority communities. The research projects supported by the present RCMI proposal will be innovative as we propose to utilize a programmatic structure involving partnerships with major research universities, an NIH-supported Center for Minority Health and Health Disparities and an NIH-funded center for translational sciences.

Public Health Relevance

Cancer remains a major public health problem, especially among African Americans. Across the U.S., and particularly in Louisiana, the number of new cancer cases and cancer-related deaths is significantly higher in African Americans than Caucasians. Xavier's RCMI Center for Cancer Research will continue to support research to improve health outcomes for individuals with cancer, especially those from minority populations.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12MD007595-10
Application #
9460920
Study Section
Special Emphasis Panel (ZMD1)
Program Officer
Das, Rina
Project Start
2009-09-24
Project End
2019-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Xavier University of Louisiana
Department
Type
University-Wide
DUNS #
020857876
City
New Orleans
State
LA
Country
United States
Zip Code
70125
Al-Horani, Rami A; Afosah, Daniel K (2018) Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev 38:1974-2023
Mei, Suyu; Flemington, Erik K; Zhang, Kun (2018) Transferring knowledge of bacterial protein interaction networks to predict pathogen targeted human genes and immune signaling pathways: a case study on M. tuberculosis. BMC Genomics 19:505
Aqeel, Salem M; Huang, Zhongyuan; Walton, Jonathan et al. (2018) Polyvinylidene Fluoride (PVDF)/Polyacrylonitrile (PAN)/Carbon Nanotube Nanocomposites for Energy Storage and Conversion. Adv Compos Hybrid Mater 1:185-192
Zheng, Shilong; Guo, Shanchun; Zhong, Qiu et al. (2018) Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett 9:149-154
Dai, Lu; Smith, Charles D; Foroozesh, Maryam et al. (2018) The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer 142:2153-2162
Drennen, Callie; Gorse, Erin; Stratford Jr, Robert E (2018) Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells. J Pharm Sci 107:1194-1203
Zhang, Wensheng; Flemington, Erik K; Zhang, Kun (2018) Driver gene mutations based clustering of tumors: methods and applications. Bioinformatics 34:i404-i411
Li, Xiang; Zhang, Changde; Guo, Shanchun et al. (2018) Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents. Eur J Med Chem 157:978-993
Patanapongpibul, Manee; Zhang, Changde; Chen, Guanglin et al. (2018) Optimization of diarylpentadienones as chemotherapeutics for prostate cancer. Bioorg Med Chem 26:4751-4760
Thomas-Porch, Caasy; Li, Jie; Zanata, Fabiana et al. (2018) Comparative proteomic analyses of human adipose extracellular matrices decellularized using alternative procedures. J Biomed Mater Res A 106:2481-2493

Showing the most recent 10 out of 244 publications